Cargando…

Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study

BACKGROUND: We investigated the efficacy and safety of apararenone (MT-3995), a non-steroidal compound with mineralocorticoid receptor agonist activity, in patients with stage 2 diabetic nephropathy (DN). METHODS: The study had two parts: a dose–response, parallel-group, randomized, double-blind, pl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wada, Takashi, Inagaki, Masaya, Yoshinari, Toru, Terata, Ryuji, Totsuka, Naoko, Gotou, Miki, Hashimoto, Gaia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880964/ https://www.ncbi.nlm.nih.gov/pubmed/32974732 http://dx.doi.org/10.1007/s10157-020-01963-z

Ejemplares similares

Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers
por: Nakamura, Tadakatsu, et al.
Publicado: (2020)

Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study
por: Inagaki, Nobuya, et al.
Publicado: (2015)

Safety and Efficacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension
por: Aman, Michael G., et al.
Publicado: (2017)

The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies
por: Baldwin, David S, et al.
Publicado: (2016)

Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study†
por: Inagaki, N, et al.
Publicado: (2013)

Patients’ Perception on the Nutritional Therapy for Diabetic Nephropathy
por: Shide, Kenichiro, et al.
Publicado: (2014)

Dark Rearing Promotes the Recovery of Visual Cortical Responses but Not the Morphology of Geniculocortical Axons in Amblyopic Cat
por: Gotou, Takahiro, et al.
Publicado: (2021)

Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study in Japan
por: Wada, Takashi, et al.
Publicado: (2022)

Clinical impact of endocapillary proliferation with modified cutoff points in IgA nephropathy patients
por: Kaihan, Ahmad Baseer, et al.
Publicado: (2019)

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension
por: Bull, Janet, et al.
Publicado: (2015)

Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study
por: Arnold, Lesley M., et al.
Publicado: (2016)

Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label Extension
por: Koh, Jung-Min, et al.
Publicado: (2016)

Can an Open-Label Placebo Be as Effective as a Deceptive Placebo? Methodological Considerations of a Study Protocol
por: Druart, Leo, et al.
Publicado: (2020)

Lactobacillus helveticus SBT2171 Alleviates Perennial Allergic Rhinitis in Japanese Adults by Suppressing Eosinophils: A Randomized, Double-Blind, Placebo-Controlled Study
por: Yamashita, Maya, et al.
Publicado: (2020)

Seasonal proteinuria changes in IgA nephropathy patients after proteinuria remission
por: Inagaki, Koji, et al.
Publicado: (2017)

Use of medium chain triglyceride (MCT) oil in subjects with Alzheimer's disease: A randomized, double‐blind, placebo‐controlled, crossover study, with an open‐label extension
por: Juby, Angela G., et al.
Publicado: (2022)

Systematic Evaluation of the T30 Neurostimulator Treatment for Tinnitus: A Double-Blind Randomised Placebo-Controlled Trial with Open-Label Extension
por: Hall, Deborah Ann, et al.
Publicado: (2022)

The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study
por: Frank, Samuel, et al.
Publicado: (2022)

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
por: Zhang, Hongyan, et al.
Publicado: (2016)

OR27-4 Placebo-Controlled and Open-Label Extension Study of a Novel Hepatic-Targeted Antisense Cimdelirsen (IONIS-GHR-LRx) Under Investigation in Acromegaly Patients
por: Bhanot, Sanjay, et al.
Publicado: (2022)

Patients’ experiences treated with open-label placebo versus double-blind placebo: a mixed methods qualitative study
por: Haas, Julia W., et al.
Publicado: (2022)

A qualitative study of imaginary pills and open-label placebos in test anxiety
por: Buergler, Sarah, et al.
Publicado: (2023)

Assessment of Fetal Autonomic Nervous System Activity by Fetal Magnetocardiography: Comparison of Normal Pregnancy and Intrauterine Growth Restriction
por: Fukushima, Akimune, et al.
Publicado: (2011)

Polyethylene glycol 3350 plus electrolytes for chronic constipation: a 2-week, randomized, double-blind, placebo-controlled study with a 52-week open-label extension
por: Nakajima, Atsushi, et al.
Publicado: (2019)

Can the Open Label Placebo Rationale Be Optimized?
por: Heiss, Uwe, et al.
Publicado: (2021)

Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled, Dose Escalation Study
por: Packham, David K., et al.
Publicado: (2016)

ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension
por: Gault, Laura M., et al.
Publicado: (2016)

Botulinum neurotoxin treatment in jerky and tremulous functional movement disorders: a double-blind, randomised placebo-controlled trial with an open-label extension
por: Dreissen, Yasmine Emma Maria, et al.
Publicado: (2019)

Immunomodulatory Effect of Withania somnifera (Ashwagandha) Extract—A Randomized, Double-Blind, Placebo Controlled Trial with an Open Label Extension on Healthy Participants
por: Tharakan, Ajit, et al.
Publicado: (2021)

Identification of an Interaction between VWF rs7965413 and Platelet Count as a Novel Risk Marker for Metabolic Syndrome: An Extensive Search of Candidate Polymorphisms in a Case-Control Study
por: Nakatochi, Masahiro, et al.
Publicado: (2015)

High‐dose linaclotide is effective and safe in patients with chronic constipation: A phase III randomized, double‐blind, placebo‐controlled study with a long‐term open‐label extension study in Japan
por: Fukudo, Shin, et al.
Publicado: (2018)

Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study
por: Seino, Yutaka, et al.
Publicado: (2012)

Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension
por: Vucic, Steve, et al.
Publicado: (2023)

Why do open-label placebos work? A randomized controlled trial of an open-label placebo induction with and without extended information about the placebo effect in allergic rhinitis
por: Schaefer, Michael, et al.
Publicado: (2018)

Can open label placebos improve pain and gluten tolerance via open label placebos in fibromyalgia patients? A study protocol for a randomised clinical trial in an outpatient centre
por: Paschke, Lena, et al.
Publicado: (2023)

Silymarin for the Prevention of Contrast-Induced Nephropathy: A Placebo-Controlled Clinical Trial
por: Sedighifard, Zohreh, et al.
Publicado: (2016)

Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study
por: Ito, Daisuke, et al.
Publicado: (2017)

An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression
por: Zand, Ladan, et al.
Publicado: (2019)

C5a receptor inhibitor avacopan in immunoglobulin A nephropathy—an open-label pilot study
por: Bruchfeld, Annette, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9cjg7co65cduqi4mav6uonbdi6